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Abstract
Introduction Activated leukocyte cell adhesion molecule
(ALCAM) (CD166) is an immunoglobulin molecule that has
been implicated in cell migration. The present study examined
the expression of ALCAM in human breast cancer and assessed
its prognostic value.
Methods The immunohistochemical distribution and location of
ALCAM was assessed in normal breast tissue and carcinoma.
The levels of ALCAM transcripts in frozen tissue (normal breast,
n = 32; breast cancer, n = 120) were determined using real-
time quantitative PCR. The results were then analyzed in relation
to clinical data including the tumor type, the grade, the nodal
involvement, distant metastases, the tumor, node, metastasis
(TNM) stage, the Nottingham Prognostic Index (NPI), and
survival over a 6-year follow-up period.
Results Immunohistochemical staining on tissue sections in
ducts/acini in normal breast and in breast carcinoma was
ALCAM-positive. Differences in the number of ALCAM
transcripts were found in different types of breast cancer. The
level of ALCAM transcripts was lower (P = 0.05) in tumors from
patients who had metastases to regional lymph nodes
compared with those patients without, in higher grade tumors
compared with Grade 1 tumors (P < 0.01), and in TNM Stage 3
tumors compared with TNM Stage 1 tumors (P < 0.01). Tumors
from patients with poor prognosis (with NPI > 5.4) had
significantly lower levels (P  = 0.014) of ALCAM transcripts
compared with patients with good prognosis (with NPI < 3.4),
and tumors from patients with local recurrence had significantly
lower levels than those patients without local recurrence or
metastases (P = 0.04). Notably, tumors from patients who died
of breast cancer had significantly lower levels of ALCAM
transcripts (P = 0.0041) than those with primary tumors but no
metastatic disease or local recurrence. Patients with low levels
of ALCAM transcripts had significantly (P  = 0.009) more
incidents (metastasis, recurrence, death) compared with
patients with primary breast tumors with high levels of ALCAM
transcripts.
Conclusions In the present panel of breast cancer specimens,
decreased levels of ALCAM correlated with the nodal
involvement, the grade, the TNM stage, the NPI, and the clinical
outcome (local recurrence and death). The data suggest that
decreased ALCAM expression is of clinical significance in
breast cancer, and that reduced expression indicates a more
aggressive phenotype and poor prognosis.
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Introduction
The breast is the most frequent site of cancer in women
(excluding skin cancer) and ranks second to lung cancer in
the number of deaths in women [1]. It is generally accepted
that important prognostic factors in breast cancer include
the size of the primary breast tumor (included in tumor,
node, metastasis [TNM] staging), the histologic type, the
histologic grade, the presence or absence of regional/axil-
lary lymph node metastases (included in the TNM staging
system), the presence or absence of distant metastases
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(included in the TNM staging system), and the presence or
absence of estrogen receptors and progesterone recep-
tors (see review in[2]). Research for other prognostic fac-
tors is ongoing with the goal to predict aggressiveness and
response to treatment.
Activated leukocyte cell adhesion molecule (ALCAM) is a
glycoprotein of the immunoglobulin superfamily. ALCAM
has been identified in multiple species and has different
names depending on the species and laboratory that
described it: chicken neural adhesion molecule BEN/SC-
1/DM-GRASP [3-5], rat KG-CAM [6], fish neurolin [7],
human melanoma metastasis clone D (MEMD) [8], mouse/
human CD166 [9,10], and rat HB2 [11,12]. ALCAM has
five extracellular immunoglobulin domains (two NH2-termi-
nal, membrane-distal variable- [V]-type folds and three
membrane-proximal constant- [C2]-type immunoglobulin
folds), a transmembrane region, and a short cytoplasmic tail
[13]. It is involved in both homotypic/homophilic adhesion
and heterotypic/heterophilic (to CD6) adhesion [13,14].
ALCAM has been shown to be involved in capillary tube for-
mation [15] and in vessel invasion into cartilage in vitro
[16].
ALCAM has been studied in two tumor types malignant
melanoma [17] and prostate carcinoma [18]. In 1998
Degen and colleagues isolated MEMD in human melanoma
cell lines and found a correlation with aggregation and
enhanced metastatic ability [8]. MEMD/ALCAM was
involved in melanoma cell–melanoma cell interactions, sug-
gesting a homophilic interaction between tumor cells [8].
van Kempen and colleagues [17] studied human melano-
cytic lesions and found that ALCAM expression correlated
with melanoma progression. Approximately one-half of
melanoma metastases had ALCAM positivity. The authors
concluded that ALCAM plays a role in melanoma tumor
progression. Using chip-based RNA transcript analysis,
Kristiansen and colleagues [18] studied ALCAM in pros-
tate cancer and found that ALCAM expression is often
altered in prostate carcinoma. They theorized that it may be
involved in progression of disease.
Only one previous work has mentioned ALCAM in breast
carcinoma. Degen and colleagues [8] performed northern
blot analysis of MEMD mRNA and found expression in the
MCF-7 mammary carcinoma cell line. Our laboratory is
evaluating the role of ALCAM in breast carcinoma. Studies
have shown that ALCAM is present in breast cancer cell
lines and resected breast tumors [19]. Antibody to ALCAM
decreases proliferation of breast cancer cells and
decreases the adhesion of breast cancer cells to each
other [19]. Proliferation and adhesion are both features that
are critical to tumor cell growth and metastases. With the
data on the other tumor types and data from our laboratory,
we decided to evaluate ALCAM expression in breast carci-
noma using tissue from patients who have been followed
for 6 years and have been studied extensively [20-25] to
determine whether ALCAM expression is a prognostic indi-
cator. Our results suggest that decreased ALCAM expres-
sion is of clinical significance in breast cancer.
Materials and methods
Materials
The RNA extraction kit and the RT kit were obtained from
AbGene Ltd (Surrey, UK). PCR primers were designed
using Beacon Designer (Palo Alto, CA, USA) and synthe-
sized by Invitrogen Ltd (Paisley, UK). Molecular biology-
grade agarose and the DNA ladder were from Invitrogen
(Carlsbad, CA, USA). The master mix for routine PCR and
quantitative PCR (Qabsolute) were from AbGene Ltd.
Mouse monoclonal antibody ALCAM/CD166 (for immuno-
histochemistry) was obtained from Novocastra Laborato-
ries (Newcastle upon Tyne, UK). Peroxidase conjugated
anti-mouse antibodies were from Sigma (Poole, UK) and a
biotin universal kit was from Dako Ltd (Carpinteria, CA,
USA).
Sample collection
Primary breast cancer tissues (n = 120) and non-neoplas-
tic mammary tissue (from the same mastectomy speci-
mens) (n = 32) were collected immediately after surgery
(mastectomy) and stored in the deep freezer (-70°C) until
use (collected with approval of local ethical committees in
Cardiff and London). Details of histology were obtained
from pathology reports (Table 1). Patients were routinely
followed clinically after surgery and their details stored in a
database. The median follow-up period was 72 months.
The presence of tumor cells in the tissues were independ-
ently assessed by a specialist pathologist using H & E
stained frozen sections. Where normal non-neoplastic
mammary tissues were used, no tumor cells were found in
the sections.
Additional formalin-fixed, paraffin-embedded archival tissue
with normal breast (from mastectomy specimens with can-
cer elsewhere and from breast reduction surgeries) and
with breast cancer were used for immunohistochemical
staining. (Institutional Review Board approval was obtained
for tissue obtained in the United States.)
Tissue processing, RNA extraction, and cDNA synthesis
Frozen sections of tissue were cut at a thickness of 5–10
µm and were kept for immunohistochemistry and routine
histology. Other 15–20 µm sections were mixed and
homogenized using a hand-held homogenizer, in ice-cold
RNA extraction solution. The concentration of RNA was
determined using an UV spectrophotometer. Reverse tran-
scription was carried out using a RT kit with an anchored
oligo dT primer supplied by AbGene, using 1 µg total RNA
a in 96-well plate. The quality of cDNA was verified using β-Available online http://breast-cancer-research.com/content/6/5/R478
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actin primers (5'-caggaggttgaaggactaaa-3' and 5'-gggat-
cagttttctttgtca-3').
Quantitative analysis of ALCAM
The level of ALCAM transcripts from the earlier prepared
cDNA was determined using a real-time quantitative PCR,
based on the Amplifluor™ technology [26], modified from a
method previously reported [22,27]. Briefly, pairs of PCR
primers were similarly designed using the Beacon Designer
software (version 2) (5'-caggaggttgaaggactaaa-3' and 5'-
gggatcagttttctttgtca-3'), but to one of the primers an addi-
tional sequence, known as the Z sequence (5'-actgaacct-
gaccgtaca-3'), which is complementary to the universal Z
probe [26] (Intergen Inc., Livingston, UK), was added to
one of the primers (ALCAMZr). A Taqman detection kit for
β-actin was purchased from Perkin-Elmer (Surrey, UK).
The reaction was carried out using the following: Hot-start
Q-master mix (Abgene), 10 pmol specific forward primer, 1
pmol reverse primer that has the Z sequence, 10 pmol
FAM-tagged probe (Intergen Inc.), and cDNA from approx-
imately 50 ng RNA [20,21]. The reaction was carried out
using IcyclerIQ™ (Bio-Rad, Hemel Hempstead, UK), which
is equipped with an optic unit that allows real-time detec-
tion of 96 reactions, using the following conditions: 94°C
for 12 min, 50 cycles of 94°C for 15 s, 55°C for 40 s, and
72°C for 20 s [21,22]. The levels of the transcripts were
generated from a standard (purified plasmid with known
quantity [28]) that was simultaneously amplified with the
samples, and they are presented in this paper as relative
levels calculated from the internal standard. The epithelial
content within the tumors was taken into account by nor-
malizing ALCAM against cytokeratin 19. The cytokeratin 19
forward and reverse primers were 5'-caggtccgaggttact-
gac-3' and 5'-actgaacctgaccgtacacactttctgccagtgtgtcttc-
3', respectively.
Immunohistochemical staining
The procedure was similar to that previously reported, with
minor modifications [22-24]. Briefly, frozen sections of
breast tumor and non-neoplastic breast tissue were cut at
a thickness of 6 µm using a cryostat. The sections were
mounted on microscope slides, air-dried and then fixed in a
mixture of 50% acetone and 50% methanol. The sections
were then placed in 'Optimax' (Vector Laboratories Ltd,
Peterborough, UK) wash buffer for 5–10 min to rehydrate.
Sections were incubated for 20 min in a 0.6% BSA block-
ing solution and probed with the primary antibody (1:40
dilution ALCAM). Following extensive washings, sections
were incubated for 30 min in the secondary biotinylated
antibody (Multilink Swine anti-goat/mouse/rabbit immu-
noglobulin; Dako Inc.). Following washings, Avidin Biotin
Complex (Vector Laboratories Ltd) was then applied to the
sections, followed by extensive washings. Diaminobenzi-
dine chromogen (Vector Laboratories Ltd) was then added
to the sections, which were incubated in the dark for 5 min.
Sections were then counterstained in Gill's Haematoxylin
and dehydrated in ascending grades of methanol before
clearing in xylene and mounting under a coverslip.
Staining intensity was semiquantified using a method
established in our laboratory [29], modified based on that
reported by Fidler and colleagues [30]. Briefly, gray-scale
digitized images were imported into the Optimas software
(Optimas 6.0; Optimus Corp., Bothell, Washington, USA).
The intensity of the cell adhesion molecules were meas-
ured in two locations from randomly chosen cells: the cyto-
plasmic region and the intercellular adhesion region where
appropriate. Control staining (without primary antibody)
Table 1
Clinical information on patients in the study
Characteristic n
Node status
Node-negative 65
Node-positive 55
Grade
Grade 1 23
Grade 2 41
Grade 3 56
Histology
Ductal 88
Lobular 14
Other
Medullary 2
Tubular 2
Mucinous 4
Tumor, node, metastasis (TNM) stage
TNM Stage 1 69
TNM Stage 2 40
TNM Stage 3 7
TNM Stage 4 4
Clinical outcome
Disease free 87
With metastasis 6
With local recurrence 5
Died of breast cancer 16
Died of unrelated disease 6Breast Cancer Research    Vol 6 No 5    King et al.
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was used for extraction of the background staining. Inten-
sity data were exported to Excel for statistical analysis and
are presented here as the mean intensity of either the cyto-
plasmic region or membranous staining.
Formalin-fixed, paraffin-embedded breast tissue (non-neo-
plastic breast and breast cancer) were sectioned (4–5 µm
thick) and stained for ALCAM (1:40 dilution; Novocastra
Laboratories). A high-temperature unmasking technique
was utilized. Staining was performed using a Dako
Autostainer.
Statistical analysis
Statistical analysis of RNA transcript data was carried out
using the Mann–Whitney U test and the Kruskal–Wallis
test. Data for Kaplan–Meier survival curves were analyzed
with Cox proportion analysis. Statistical analysis of the
immunohistochemical staining was carried out using two-
sided two-tailed t test.
Results
ALCAM staining in normal breast and human breast 
cancer
Epithelial cells from non-neoplastic mammary tissues and
human breast carcinoma had strong immunohistochemical
staining in both formalin-fixed tissue and frozen tissue (Fig.
1). Although not the focus of this study, the areas of carci-
noma in situ seen in the sections also had positivity for
ALCAM in the epithelium. A membranous pattern of stain-
ing was seen in some specimens (Fig. 1b). Analysis of the
staining intensity of individual cells in frozen tissue sections
have shown that the cytoplasmic staining of normal epithe-
Figure 1
Immunohistochemical staining for activated leukocyte cell adhesion molecule (ALCAM) Immunohistochemical staining for activated leukocyte cell adhesion molecule (ALCAM). (a) Normal (non-neoplastic) breast tissue; formalin-fixed, 
paraffin-embedded tissue. Note staining in normal ducts. (b) Human breast carcinoma (infiltrating ductal carcinoma); formalin-fixed, paraffin-embed-
ded tissue. Note strong membranous staining in breast cancer. (c) Normal (non-neoplastic) breast tissue; frozen tissue. Note staining in normal 
ducts. (d) Human breast carcinoma; frozen tissue. Note staining of invasive breast carcinoma.Available online http://breast-cancer-research.com/content/6/5/R478
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lial cells was significantly stronger than that of tumor cells
(Fig. 2a). Membranous staining, where visible, was gener-
ally stronger than the cytoplasmic region, and normal mam-
mary epithelium displayed significantly higher intensity than
that of breast cancer cells in frozen tissue (Fig. 2b).
ALCAM transcript levels in breast cancer and normal 
tissues
Figure 3a shows that the number of ALCAM transcripts in
breast cancer was slightly higher than in non-neoplastic
breast tissue from the same mastectomy specimens (P >
0.05). Discrepancies thus appear to exist between the tran-
script levels and protein levels. Two possibilities exist. First,
the levels of ALCAM transcript and protein (as seen by
staining intensity) were probably due to the difference in
cellularity between tumor tissues and non-neoplastic mam-
mary tissues. Indeed, when the transcript levels were nor-
malized by cytokeratin 19, tumor tissues were seen to have
significantly lower levels of ALCAM (P = 0.043) (data not
shown). Second, there is the possible contribution from
infiltrating immune cells in tumor tissues.
ALCAM transcripts were identified in ductal, lobular, and
other (medullary, tubular, mucinous) forms of breast carci-
noma (Fig. 3b). When ductal and lobular tumors were com-
pared in their immunohistochemical staining intensity,
significantly stronger cytoplasmic staining of ALCAM was
seen in ductal carcinoma than in lobular tumors (P < 0.01)
(Fig. 2c).
ALCAM expression in relation to tumor grade, stage, 
lymph node involvement and prognosis
Grade 2 tumors (moderately differentiated) and Grade 3
tumors (poorly differentiated) had significantly less ALCAM
transcripts than Grade 1 tumors (well differentiated) (P <
0.01) (Fig. 4a), and the levels were decreased in tumors
from patients with TNM Stage 3 compared with TNM Stage
1 (P  < 0.01) (Fig. 4b). Tumors from patients that had
metastases in the lymph nodes had low levels of ALCAM
transcripts (P = 0.05) compared with those patients with-
out metastases in the lymph nodes (Fig. 4c). Using the Not-
tingham Prognostic Index (NPI), tumors from patients with
NPI > 5.4 (worst prognostic group) had decreased
ALCAM transcripts when compared with patients with NPI
< 3.4 (best prognostic group) (P = 0.014) (Fig. 4d).
Notably, the number of ALCAM transcripts were decreased
in tumors from patients who had local recurrence (P  =
0.04) (Fig. 5) and were significantly decreased in tumors of
patients who died from breast cancer (P = 0.0041). The
patients were divided into those with high levels and those
with low levels of ALCAM transcripts, with levels from
patients who had a moderate prognostic index (NPI-2
group) as the cut-off point. The Kaplan–Meier survival curve
Figure 2
Cytoplasmic and membranous staining intensity of activated leukocyte cell adhesion molecule (ALCAM) Cytoplasmic and membranous staining intensity of activated leukocyte cell adhesion molecule (ALCAM). (a) Cytoplasmic staining intensity of 
ALCAM of normal mammary epithelial cells and breast cancer cells (mean ± standard deviation). (b) Membranous staining intensity of ALCAM in 
normal mammary epithelial cells and breast cancer cells (mean ± standard deviation). (c) Cytoplasmic staining intensity of ALCAM in ductal and lob-
ular tumor cells (mean ± standard deviation). Ca, carcinoma.Breast Cancer Research    Vol 6 No 5    King et al.
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(Fig. 6) of all incidents (all but disease free; includes metas-
tasis, recurrence, and death) show a significant difference
(Cox proportion analysis, P = 0.009) between patients with
high levels and those with low levels of ALCAM.
Discussion
This study is the first to focus on ALCAM expression and its
prognostic value in breast carcinoma. Normal ductal epi-
thelial cells in breast tissue showed positivity to ALCAM in
immunohistochemical stains (Fig. 1). This positivity was
also seen in invasive breast carcinoma, although the levels
(both cytoplasmic and membranous) were lower than that
of normal (non-neoplastic) mammary epithelium in the
stained frozen tissue sections (Fig. 2). Immunohistochemi-
cal staining of breast tissues alone with the antibody used
would therefore not distinguish between benign cells and
malignant cells. The established pathologic criteria for car-
cinoma, including the architecture, nuclear pleomorphism,
and mitotic counts, have to be evaluated.
The level of ALCAM transcripts appears to be higher in pri-
mary tumors compared with normal (non-neoplastic) breast
tissue from the same mastectomy specimens, although it
was not statistically significant (Fig. 3a). This was in con-
trast to the immunohistochemical staining, in that individual
tumor cells stained weaker than individual normal mammary
epithelial cells in the frozen tissue samples (Fig. 2a,2b).
Possibilities for this discrepancy may rest with different epi-
thelial/tumor cell content in different tumors and the possi-
ble contribution from infiltrating immune cells.
Hematopoietic stem cells and activated T lymphocytes
express ALCAM [31-34]. The majority of leukocytes in the
formalin-fixed, paraffin-embedded breast tissue sections do
not exhibit immunohistochemical staining for ALCAM. Tis-
sue histiocytes stain with antibody to ALCAM, as do some
cells in lymphoid aggregates. One could also argue that
non-neoplastic breast tissue in areas without tumor in these
specimens is not truly 'normal'. Ductal and acinar structures
in normal breast tissue obtained from breast reduction sur-
geries, however, also showed strong immunohistochemical
staining for ALCAM. It therefore appears that ALCAM is
present normally but may have an altered expression in
tumors.
Infiltrating ductal carcinoma is the most common form of
invasive breast carcinoma. The transcript number was eval-
uated in ductal and lobular carcinomas as well as in a group
of other less frequent types of breast tumors (medullary,
tubular, and mucinous) (Fig. 3b). Differences in transcript
numbers were seen between the groups, with lobular car-
cinomas generally having less ALCAM transcripts than
ductal carcinomas, whereas the number of 'other' cases
included was too low to make an accurate assessment. The
same staining pattern of other cell adhesion molecules
(namely, E-cadherin) has also been reported [35-37]. E-
cadherin expression is lower in lobular breast carcinoma
than in infiltrating ductal carcinoma [35]. E-cadherin is con-
sidered a tumor suppressor, with loss of E-cadherin corre-
lating with invasion and metastases [38].
There was a statistically significant difference (P < 0.01) of
ALCAM transcript levels between the Grade 2 tumors
(moderately differentiated) and Grade 3 tumors (poorly dif-
ferentiated) compared with Grade 1 tumors (well
differentiated) (Fig. 4a). Higher grade tumors in general are
less differentiated, more pleomorphic, and more mitotically
active, and they exhibit a tendency for decreased ALCAM
transcript numbers.
It is well known that the presence or absence of regional/
axillary nodal metastases is an important prognostic param-
eter. ALCAM transcripts were decreased in patients with
metastases to regional nodes, although the numbers are
not statistically significant (P = 0.05) (Fig. 4c).
The TNM system for classifying tumors includes evaluation
of the tumor, regional lymph nodes, and distant metastases.
This system includes the primary tumor size and number of
lymph nodes involved in the axilla. The higher the TNM clas-
sification, the worse the patient survival rate [2]. Our study
showed that primary tumors from patients with TNM Stage
3 had significantly less (P < 0.01) ALCAM transcripts than
those with TNM Stage 1 tumors (Fig. 4b).
Another clinical parameter of prognosis is the NPI [39],
which combines tumor size, lymph node stage and histo-
Figure 3
Activated leukocyte cell adhesion molecule (ALCAM) numbers in  breast cancer Activated leukocyte cell adhesion molecule (ALCAM) numbers in 
breast cancer. (a) The ALCAM transcript number in breast cancer and 
non-neoplastic tissue from the same mastectomy specimens (mean ± 
standard deviation). (b) The ALCAM transcript number and tumor type. 
The 'others' category includes two cases of medullary carcinoma, two 
cases of tubular carcinoma, and four cases of mucinous carcinoma 
(mean ± standard deviation).Available online http://breast-cancer-research.com/content/6/5/R478
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Figure 4
Activated leukocyte cell adhesion molecule (ALCAM) transcript numbers and grade tumor, node, metastasis (TNM) stage, nodal status, and Notting- ham Prognostic Index (NPI) Activated leukocyte cell adhesion molecule (ALCAM) transcript numbers and grade tumor, node, metastasis (TNM) stage, nodal status, and Notting-
ham Prognostic Index (NPI). (a) The ALCAM transcript number and the grade of tumor. Grade 1 is well differentiated, Grade 2 is moderately differ-
entiated, and Grade 3 is poorly differentiated (mean ± standard deviation). (b) The ALCAM transcript number and the TNM staging (mean ± 
standard deviation). Note that there were only four patients with TNM Stage 4 disease. (c) The ALCAM transcript number and regional nodal status 
(mean ± standard deviation). (d) The ALCAM transcript number and NPI. NPI-1 represents the good prognostic group with scores < 3.4, NPI-2 rep-
resents the moderate prognostic group with scores of 3.4–5.4, and NPI-3 represents the poor prognostic group with scores > 5.4 (mean ± stand-
ard deviation).Breast Cancer Research    Vol 6 No 5    King et al.
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logic grade into a formula to determine prognostic groups.
The group with NPI < 3.4 has the best prognosis, NPI > 5.4
is associated with poor prognosis, and NPI = 3.4–5.4 has
an intermediate prognosis. The scoring system has been
validated in prospective studies [40], and is used in coun-
tries such as the United Kingdom [41]. Interestingly, the
ALCAM transcript number was lower in the worst NPI prog-
nostic group (NPI > 5.4) when compared with the best
prognostic group (NPI < 3.4) (P = 0.014) (Fig. 4d).
When patients were divided into categories of disease free,
with metastases, with local recurrence, or death due to
breast cancer, there was a significant difference in the
ALCAM transcript number for those with local recurrence
(P = 0.04) or those that died of breast cancer (P = 0.0041)
compared with those that were disease free after excision
of primary tumor (Fig. 5). Altogether, the present data
strongly suggest that a lower ALCAM transcript number in
the primary tumor is associated with a worse prognosis.
This is confirmed in the Kaplan–Meier survival curve (Fig.
6), which shows that patients with low levels of ALCAM
have more incidents of metastasis, recurrence, or death
when compared with patients with high levels of ALCAM
RNA in the primary tumor.
Only two types of cancer have been previously evaluated
for ALCAM – melanoma and prostate cancer. With
melanoma there was increased staining for ALCAM during
the vertical growth phase of the tumor [17]. This would sug-
gest that ALCAM is involved in tumor growth and progres-
sion. ALCAM expression was decreased in high-grade
prostate carcinoma, suggesting that altered expression
correlated with tumor grade [18]. Notably, in breast cancer
there does appear to be distinct differences in ALCAM
transcript levels in patients that correspond to prognosis.
We hypothesize that altered expression of ALCAM may be
related to tumor proliferation, adhesion, and metastatic
capability. During the 6-year follow-up of the patients used
in the present study, decreased ALCAM transcripts in the
primary tumors correlated with nodal involvement, higher
grade tumors, higher TNM stage, worse NPI index,
presence of local recurrence, and death due to breast can-
cer. Clearly the data suggest that decreased ALCAM
expression in the primary tumor is of clinical significance in
breast cancer, and that reduced expression indicates a
more aggressive phenotype and poor prognosis.
Figure 5
The activated leukocyte cell adhesion molecule (ALCAM) transcript  number and clinical outcomes The activated leukocyte cell adhesion molecule (ALCAM) transcript 
number and clinical outcomes. Patients were divided into disease free 
(Dis. Free), with metastasis (With Met.), with local recurrence (With 
Loc. Recur.), or died of breast cancer (Died Br. Ca.) (excluding patients 
who died of other unrelated diseases) (mean ± standard deviation).
Figure 6
Kaplan–Meier incident curve including metastasis, recurrence, and  death (all but disease free) Kaplan–Meier incident curve including metastasis, recurrence, and 
death (all but disease free). Patients were divided into two groups 
based on the level of transcripts of activated leukocyte cell adhesion 
molecule (ALCAM). Pink line, patients with high levels of ALCAM; 
green line, patients with low levels of ALCAM. Pink line, mean time to 
incident was 100.5 months. Green line, mean time to incident was 79.6 
months. Cox proportion analysis between the two groups, P = 0.009.Available online http://breast-cancer-research.com/content/6/5/R478
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We hypothesize that the reduced expression of ALCAM, a
molecule involved in cell adhesion, may allow the tumor
cells to disaggregate, allowing cells to enter the circulation
and metastasize, a phenomenon mirrored by other cell
adhesion molecules such as E-cadherin [35-38]. ALCAM is
known to colocalize with E-cadherin in epithelial cells [42].
With E-cadherin, a number of mechanisms operate for its
reduction in cancer cells, including shedding of the cad-
herin extracellular domain, redistribution from the cell sur-
face to the cytoplasm or from cell–cell adhesion areas to
other areas of the membrane, and transcriptional abnormal-
ities as a result of gene promoter hypermethylation [38].
The current study has shown that both cytoplasmic staining
and membranous staining of ALCAM are lower in cancer
cells, strongly arguing the possibility of transcriptional aber-
ration. It would be important to examine such events as pro-
moter methylation in the future.
The present study suggests that although there is no signif-
icant difference between normal breast tissue and breast
cancer in ALCAM transcript number (Fig. 3a), and immuno-
histochemistry alone does not distinguish between benign
and malignant cells in the breast, PCR can be used to iden-
tify more aggressive tumors.
Conclusions
ALCAM is a glycoprotein that is involved with cellular adhe-
sion, proliferation, and tumor progression. In breast carci-
noma, decreased ALCAM transcripts in the primary tumors
correlate with nodal involvement, higher grade tumors,
higher TNM stage, worse NPI index, the presence of local
recurrence, and death due to breast cancer. This study
suggests that the level of ALCAM expression in primary
breast carcinoma has clinical significance, and that
reduced expression indicates a more aggressive pheno-
type and poor prognosis.
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